Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report), ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) investors will be delighted, with the company turning in some strong numbers with its latest results. Revenues of US$40m beat estimates by a substantial 30 ...

Reports Q4 revenue $16.361M, consensus $7.71M. “We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin ...

Mersana Therapeutics has a one year low of $0.46 and a one year high of $6.28. The business’s 50-day simple moving average is $0.77 and its 200 day simple moving average is $1.55.

Mersana Therapeutics announced promising Phase 1 results for Emi-Le in TNBC and received Fast Track designation from the FDA. Mersana Therapeutics, Inc. announced positive initial Phase 1 clinical ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus estimated revenue ...

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.16 per share a year ago.

On Tuesday, 11 March 2025, Mersana Therapeutics (NASDAQ ... And I think even in their public communications, they were looking more towards frontline therapy. And one of the things that they ...

Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2024 Conference Call. Currently all participants are in a listen-only mode. There will be a question-and-answer ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) investors will be delighted, with the company turning in some strong numbers with its latest results. Revenues of US$40m beat estimates by a substantial 30% ...